Clinical trials: Neoplasms, Solid Tumor
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems.
- Trial name
- BBT-II (NCT04829539)
- Testing
- Behavioral Intervention, Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 153 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Rochester NCORP Research Base
Pediatric Cancer
Physical Activity in Pediatric Cancer (PAPEC)
The aim of this randomized controlled trial on Physical Activity and Pediatric Cancer (PAPEC) is to assess the impact of an exercise program intervention in pediatric cancer patients undergoing chemotherapy for solid tumors.
- Trial name
- PAPEC (NCT01645436)
- Testing
- exercise training
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Universidad Europea de Madrid
Neoplasms, Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2…
- Conditions
- Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm
- Trial name
- NCT07631871
- Testing
- Zanidatamab
- Volunteers
- 10 people
- Sponsor
- Haihua Yuan
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
This study is being done to investigate the safety, tolerability and anti-tumor activity of pembrolizumab (MK-3475) in participants with advanced triple negative breast cancer (TNBC) (Cohort A), advanced head and neck cancer…
- Trial name
- NCT01848834
- Testing
- Pembrolizumab
- Volunteers
- 297 people
- Sponsor
- Merck Sharp & Dohme LLC
Rhabdomyosarcoma
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Background: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface.
- Trial name
- NCT06865664
- Testing
- fludarabine, cyclophosphamide, cetuximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Bone Metastases
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
A multi-center, randomized, double-blind, parallel controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW032 and Xgeva® in patients with bone metastases from solid tumors.
- Trial name
- NCT04812509
- Testing
- MW032, Xgeva
- Where
- China
- Volunteers
- 708 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Inoperable Solid Tumors or Lymphomas
Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas
Local treatment of unresectable tumors is challenging, particularly with radioactivity. Current practice relies on external beam irradiation or on a variety of medical devices for brachytherapy.
- Trial name
- NCT03188328
- Testing
- AvidinOX, 177Lu-ST2210
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Alfasigma S.p.A.
Solid Tumor
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
An open-label, randomized, single-dose, two-way crossover bioequivalence study to compare two strengths (10 mg and 20 mg) of IMP4297 capsules in healthy Chinese subjects under fasting condition.
- Trial name
- NCT05390944
- Testing
- IMP4297(20mg), IMP4297(10mg)
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.
Solid Tumor, Childhood, Brain Tumor, Pediatric
Social Emotional Development in Young Children With Cancer
Many children with cancer are diagnosed in early childhood, and as such, will likely miss key social experiences such as participation in preschool or kindergarten, playing on playgrounds, and other normative experiences.
- Trial name
- NCT03086421
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- St. Jude Children's Research Hospital
Breast Cancer, Colon Cancer
Stress-Reducing Intervention in Patients With Colorectal and Breast Cancer
The goal of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in 2 cohorts of patients.
- Trial name
- SRI-BrCa_CRC (NCT06281145)
- Testing
- Heart-rate variability biofeedback intervention
- Where
- Slovakia
- Volunteers
- 100 people
- Sponsor
- Comenius University
Advanced Solid Tumor
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
INC280 will be administered to Japanese patients with advanced soid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- NCT01546428
- Testing
- INC280
- Where
- 2 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Solid Neoplasms, Colorectal Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
- Conditions
- Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
- Trial name
- NCT03833700
- Testing
- E7386
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Advanced Solid Tumor
Study of AGEN1571 in Participants With Advanced Solid Tumors
This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of AGEN1571 both as a monotherapy and in combination…
- Trial name
- NCT05377528
- Testing
- AGEN1571, Balstilimab, Botensilimab
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Agenus Inc.
Solid Tumor Malignancies
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors
The goal of this phase I, first-in-human, open-label study is to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SWA1211 in subjects with advanced solid tumors.
- Trial name
- NCT07363967
- Testing
- SWA1211
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing StoneWise Technology Co., Ltd
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03725436
- Testing
- MDM2/MDMX Inhibitor ALRN-6924, Paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
An open, single-arm, multi-center Phase II clinical study of ENVAFOLIMAB single-agent treatment in patients with advanced solid tumors,to compare the overall response rate of TMB-high and TMB-Low,to determine the cut off value…
- Trial name
- NCT04891198
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 126 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Neoplasms
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.
- Trial name
- NCT03416816
- Testing
- DSP-0337
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Solid Tumors
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.
- Trial name
- NCT03077607
- Testing
- Talazoparib, Itraconazole, Rifampin
- Where
- 7 sites in Hungary, Moldova and 2 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Ovarian Cancer, Breast Cancer
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced…
- Conditions
- Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
- Trial name
- LNCB74-01 (NCT06774963)
- Testing
- LNCB74
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- LigaChem Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.